SCHEDULE: Jane Street Discloses Stake in Co-Diagnostics

Jane Street Group, LLC, Jane Street Capital, LLC, and Jane Street Global Trading, LLC have collectively reported beneficial ownership of 6.4% of Co-Diagnostics, Inc. common stock.

Summary

• Jane Street Group, LLC, along with its affiliates Jane Street Capital, LLC and Jane Street Global Trading, LLC, have filed a Schedule 13G.
• This filing indicates their beneficial ownership of 236,359 shares of Co-Diagnostics, Inc. common stock.
• This represents approximately 6.4% of the total class of securities.
• The filing is made under Rule 13d-1(b), indicating the reporting persons are brokers or dealers registered under Section 15 of the Securities Exchange Act of 1934.
• The reporting persons have shared power to vote and dispose of these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership by an institutional investor and does not inherently signal positive or negative performance for the company.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors who acquire more than 5% of a company's outstanding securities. This filing indicates a significant passive stake by Jane Street, a well-known quantitative trading firm, in Co-Diagnostics, Inc.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding significant institutional ownership, which can influence market perception and trading dynamics.

Key Dates

Keywords

Schedule 13G, Jane Street, Co-Diagnostics, beneficial ownership, common stock, broker-dealer, SEC filing